Opiate Addiction Clinical Trials 2023

Opiate Addiction Clinical Trials 2023

Opiate Addiction research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in opiate addiction clinical trials today.

Opiate Addiction Clinical Trials

Here are the 6 most popular medical studies for opiate addiction

Popular filter options for opiate addiction trials

Opioid Use Disorder Clinical Trials

View 48 Opioid Use Disorder medical studies.

OUD Clinical Trials

View 46 OUD medical studies.

Phase 3 Opiate Addiction Clinical Trials

View 91 phase 3 opiate addiction medical studies.

Opiate Addiction Clinical Trials With No Placebo

View 91 opiate addiction medical studies that do not have a placebo group.

View More Opiate Addiction Trials

See another 71 medical studies focused on opiate addiction.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to opiate addiction

What are the top hospitals conducting opiate addiction research?

In the battle against opiate addiction, top hospitals across the United States are tirelessly working to develop effective treatments and interventions. One such institution is Boston Medical Center in Boston, which currently has six active clinical trials focused on opiate addiction. With a total of 11 trials conducted thus far, their commitment to tackling this crisis was evident from their inaugural trial in 2009. Another notable player in this field is the University of Kentucky located in Lexington, with five ongoing opiate addiction trials and a solid track record of nine completed studies since their first trial back in 2006.

Notably joining these renowned hospitals is Gateway Community Services based in Jacksonville. Despite having a smaller number of three active opiate addiction trials and four completed studies to its name, Gateway Community Services made significant strides by embarking on its first recorded opiate addiction trial as recent as 2020—a testament to their dedication towards combating this pressing issue.

Closer to home for some patients can be found at Massachusetts General Hospital HOPE Clinic situated within Boston itself; it shares similar progress with three current open clinical tests along-side three prior endeavors that all began further fueling research during the year2020.

Lastly but not least important among these leading institutions stands out Pregnancy Recovery Center at Magee-Womens Hospital of UPMC positioned firmly within Pittsburgh's healthcare landscape specializing primarily catered towards women facing opioid dependency issues; actively participating through conducting three different active investigations while completing another two previously initiated ones- each forming part integral contribution during past year itself displaying unwavering commitment providing aid & solutions needed for afflicted individuals

These remarkable hospitals symbolize hope for those grappling with opiate addiction by ensuring that innovative approaches are explored continuously. As they strive forward collectively underlining an urgent need encompassing diverse regions throughout America-it becomes clearer than ever before: The fight against opioid abuse demands our united resilience coupled together progressively forging ahead until every roadblock ceases existence

Which are the best cities for opiate addiction clinical trials?

When it comes to opiate addiction clinical trials, several cities emerge as prominent locations for research and treatment. Boston, Massachusetts takes the lead with 16 active trials investigating interventions like Buprenorphine Injection, Psilocybin, and Communities That HEAL. Following closely behind is Albuquerque, New mexico with 10 ongoing studies focusing on approaches such as Collaborative care Plus and Substance Use Treatment and Recovery Team (START). New york City also has 10 active trials exploring treatments including Pharmacogenetic testing and Cannabidiol (CBD). Additionally, Lexington in Kentucky and Atlanta in Georgia both have 7 active trials each that examine various interventions for opiate addiction. These cities offer individuals battling this epidemic an opportunity to participate in cutting-edge clinical research aimed at finding better solutions for recovery.

Which are the top treatments for opiate addiction being explored in clinical trials?

Clinical trials are actively exploring various treatments for opiate addiction, with Buprenorphine Injection emerging as one of the top contenders. This powerful medication is currently being tested in three active trials dedicated to combatting opiate addiction. Since its first listing in 2020, it has gained attention and involvement in a total of three all-time clinical trials focused on addressing this pressing issue. As researchers delve deeper into finding effective solutions, the potential impact of Buprenorphine Injection offers hope for individuals battling opiate addiction.

What are the most recent clinical trials for opiate addiction?

Exciting developments are underway in the field of opiate addiction treatment, with recent clinical trials offering promising options for individuals seeking recovery. Among these trials is continuous intercostal nerve block (CINB), a Phase 4 study that explores its effectiveness in managing opiate addiction. Additionally, Aurora 1:1 Drops (Indica) and Liposomal Bupivacaine have shown potential benefits as interventions for opiate addiction in Phase 2 and Phase 3 trials respectively. Another important trial investigates the use of a transcutaneous cervical vagal nerve stimulation device to address opiate addiction, while ultrasound shear wave elastography examination offers insight into this complex condition through a Phase 4 study. These groundbreaking studies pave the way towards improved solutions for those grappling with opiate addiction, highlighting an encouraging path forward.

What opiate addiction clinical trials were recently completed?

The field of opiate addiction has seen several recent clinical trials reaching completion, offering new insights and potential treatments for this pressing issue. In August 2022, Indivior Inc.'s trial on INDV-2000 concluded successfully, followed closely by BioCorRx Pharmaceuticals, Inc.'s BICX104 trial in June 2022. Notably, Go Medical Industries Pty Ltd completed their Naltrexone 380 MG study in January 2021. Among earlier accomplishments is the December 2020 completion of a Ketamine Hydrochloride trial led by the Medical University of South carolina and an Emory University-led Non invasive VN stimulation (nVNS) trial in November 2020. NYU Langone Health's Buprenorphine Naloxone study also concluded that same month. While Jacques E. Chelly's Ketamine trial wrapped up in December 2019 and Alar Pharmaceuticals Inc.'s ALA-1000 study reached its end point in September of that year.